Panagiotis A Konstantinopoulos1, Barbara Norquist2, Christina Lacchetti3, Deborah Armstrong4, Rachel N Grisham5, Paul J Goodfellow6, Elise C Kohn7, Douglas A Levine8, Joyce F Liu1, Karen H Lu9, Dorinda Sparacio10, Christina M Annunziata11. 1. Dana-Farber Cancer Institute, Boston, MA. 2. University of Washington Medicine, Seattle, WA. 3. American Society of Clinical Oncology, Alexandria, VA. 4. Johns Hopkins, Baltimore, MD. 5. Memorial Sloan Kettering Cancer Center, New York, NY. 6. Ohio State University Comprehensive Cancer Center, Columbus, OH. 7. Gynecologic Cancer Therapeutics, National Cancer Institute, Bethesda, MD. 8. NYU Langone Health, New York, NY. 9. The University of Texas MD Anderson Cancer Center, Houston,TX. 10. Patient Representative, Hightstown, NJ. 11. Women's Malignancies Branch, National Cancer Institute, Bethesda, MD.
Abstract
PURPOSE: To provide recommendations on genetic and tumor testing for women diagnosed with epithelial ovarian cancer based on available evidence and expert consensus. METHODS: A literature search and prospectively defined study selection criteria sought systematic reviews, meta-analyses, randomized controlled trials (RCTs), and comparative observational studies published from 2007 through 2019. Guideline recommendations were based on the review of the evidence. RESULTS: The systematic review identified 19 eligible studies. The evidence consisted of systematic reviews of observational data, consensus guidelines, and RCTs. RECOMMENDATIONS: All women diagnosed with epithelial ovarian cancer should have germline genetic testing for BRCA1/2 and other ovarian cancer susceptibility genes. In women who do not carry a germline pathogenic or likely pathogenic BRCA1/2 variant, somatic tumor testing for BRCA1/2 pathogenic or likely pathogenic variants should be performed. Women with identified germline or somatic pathogenic or likely pathogenic variants in BRCA1/2 genes should be offered treatments that are US Food and Drug Administration (FDA) approved in the upfront and the recurrent setting. Women diagnosed with clear cell, endometrioid, or mucinous ovarian cancer should be offered somatic tumor testing for mismatch repair deficiency (dMMR). Women with identified dMMR should be offered FDA-approved treatment based on these results. Genetic evaluations should be conducted in conjunction with health care providers familiar with the diagnosis and management of hereditary cancer. First- or second-degree blood relatives of a patient with ovarian cancer with a known germline pathogenic cancer susceptibility gene variant should be offered individualized genetic risk evaluation, counseling, and genetic testing. Clinical decision making should not be made based on a variant of uncertain significance. Women with epithelial ovarian cancer should have testing at the time of diagnosis.
PURPOSE: To provide recommendations on genetic and tumor testing for women diagnosed with epithelial ovarian cancer based on available evidence and expert consensus. METHODS: A literature search and prospectively defined study selection criteria sought systematic reviews, meta-analyses, randomized controlled trials (RCTs), and comparative observational studies published from 2007 through 2019. Guideline recommendations were based on the review of the evidence. RESULTS: The systematic review identified 19 eligible studies. The evidence consisted of systematic reviews of observational data, consensus guidelines, and RCTs. RECOMMENDATIONS: All women diagnosed with epithelial ovarian cancer should have germline genetic testing for BRCA1/2 and other ovarian cancer susceptibility genes. In women who do not carry a germline pathogenic or likely pathogenic BRCA1/2 variant, somatic tumor testing for BRCA1/2 pathogenic or likely pathogenic variants should be performed. Women with identified germline or somatic pathogenic or likely pathogenic variants in BRCA1/2 genes should be offered treatments that are US Food and Drug Administration (FDA) approved in the upfront and the recurrent setting. Women diagnosed with clear cell, endometrioid, or mucinous ovarian cancer should be offered somatic tumor testing for mismatch repair deficiency (dMMR). Women with identified dMMR should be offered FDA-approved treatment based on these results. Genetic evaluations should be conducted in conjunction with health care providers familiar with the diagnosis and management of hereditary cancer. First- or second-degree blood relatives of a patient with ovarian cancer with a known germline pathogenic cancer susceptibility gene variant should be offered individualized genetic risk evaluation, counseling, and genetic testing. Clinical decision making should not be made based on a variant of uncertain significance. Women with epithelial ovarian cancer should have testing at the time of diagnosis.
Authors: Kathryn P Pennington; Tom Walsh; Maria I Harrell; Ming K Lee; Christopher C Pennil; Mara H Rendi; Anne Thornton; Barbara M Norquist; Silvia Casadei; Alexander S Nord; Kathy J Agnew; Colin C Pritchard; Sheena Scroggins; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher Journal: Clin Cancer Res Date: 2013-11-15 Impact factor: 12.531
Authors: Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Douglas W Blayney; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Julie M Vose; Richard L Schilsky Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: Jeanette Yuen; Suat Y Lee; Eliza Courtney; John Lim; Hazel Soh; Shao T Li; Yanni Chen; Marion McAllister; Eva K Fenwick; Joanne Ngeow Journal: Clin Genet Date: 2019-10-23 Impact factor: 4.438
Authors: Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell Journal: J Clin Oncol Date: 2012-06-18 Impact factor: 44.544
Authors: Victoria M Raymond; Stacy W Gray; Sameek Roychowdhury; Steve Joffe; Arul M Chinnaiyan; D Williams Parsons; Sharon E Plon Journal: J Natl Cancer Inst Date: 2015-11-20 Impact factor: 13.506
Authors: Kristin C Jensen; M Rajan Mariappan; Girish V Putcha; Amreen Husain; Nicki Chun; James M Ford; Iris Schrijver; Teri A Longacre Journal: Am J Surg Pathol Date: 2008-07 Impact factor: 6.394
Authors: Kevin K Lin; Maria I Harrell; Amit M Oza; Ana Oaknin; Isabelle Ray-Coquard; Anna V Tinker; Elena Helman; Marc R Radke; Carmen Say; Lan-Thanh Vo; Elaina Mann; Jeffrey D Isaacson; Lara Maloney; David M O'Malley; Setsuko K Chambers; Scott H Kaufmann; Clare L Scott; Gottfried E Konecny; Robert L Coleman; James X Sun; Heidi Giordano; James D Brenton; Thomas C Harding; Iain A McNeish; Elizabeth M Swisher Journal: Cancer Discov Date: 2018-11-13 Impact factor: 39.397
Authors: Olga Kondrashova; Minh Nguyen; Kristy Shield-Artin; Anna V Tinker; Nelson N H Teng; Maria I Harrell; Michael J Kuiper; Gwo-Yaw Ho; Holly Barker; Maria Jasin; Rohit Prakash; Elizabeth M Kass; Meghan R Sullivan; Gregory J Brunette; Kara A Bernstein; Robert L Coleman; Anne Floquet; Michael Friedlander; Ganessan Kichenadasse; David M O'Malley; Amit Oza; James Sun; Liliane Robillard; Lara Maloney; David Bowtell; Heidi Giordano; Matthew J Wakefield; Scott H Kaufmann; Andrew D Simmons; Thomas C Harding; Mitch Raponi; Iain A McNeish; Elizabeth M Swisher; Kevin K Lin; Clare L Scott Journal: Cancer Discov Date: 2017-06-06 Impact factor: 39.397
Authors: Margreet G E M Ausems; Joanne A de Hullu; Vera M Witjes; Jozé C C Braspenning; Nicoline Hoogerbrugge; Yvonne H C M Smolders; Dorien M A Hermkens; Marian J E Mourits; Marjolijn J L Ligtenberg Journal: Fam Cancer Date: 2022-05-16 Impact factor: 2.375
Authors: Stacy W Gray; Rebecca A Ottesen; Madeline Currey; Mihaela Cristea; Janet Nikowitz; Susan Shehayeb; Vanessa Lozano; Julie Hom; Julie Kilburn; Lisa N Lopez; Sam Wing; Ernesto Sosa; Jenny Shen; Michael Morris; Bedros Dilsizian; Thomas Joseph; James Shen; Camille Adeimy; Tanyanika Phillips; Bahareh Bahadini; Joyce C Niland Journal: JCO Clin Cancer Inform Date: 2022-09
Authors: A Russo; L Incorvaia; E Capoluongo; P Tagliaferri; S Gori; L Cortesi; M Genuardi; D Turchetti; U De Giorgi; M Di Maio; M Barberis; M Dessena; M Del Re; A Lapini; C Luchini; B A Jereczek-Fossa; A Sapino; S Cinieri Journal: ESMO Open Date: 2022-05-19
Authors: Jeanna M McCuaig; Emily Thain; Janet Malcolmson; Sareh Keshavarzi; Susan Randall Armel; Raymond H Kim Journal: Curr Oncol Date: 2021-04-08 Impact factor: 3.677
Authors: B Frugtniet; S Morgan; A Murray; S Palmer-Smith; R White; R Jones; L Hanna; C Fuller; E Hudson; A Mullard; A E Quinton Journal: BJOG Date: 2021-11-08 Impact factor: 7.331
Authors: Adrianne R Mallen; Claire C Conley; Lindsay Fuzzell; Dana Ketcher; Bianca M Augusto; McKenzie McIntyre; Laura V Barton; Mary K Townsend; Brooke L Fridley; Shelley S Tworoger; Robert M Wenham; Susan T Vadaparampil Journal: Support Care Cancer Date: 2020-09-25 Impact factor: 3.603